grepcent public filings, reorganized for comparison

INDV profile · all as-reported value updates

Indivior Pharmaceuticals, Inc. (INDV) as-reported value updates

Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.

Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.

Rows publish only when the later filed value differs by at least 1.0% and at least $1,000,000, after dropping differences that match under the capped trailing-zero precision rule. The delta percent is delta divided by the larger absolute filed value. Values are annual standardized facts only; metrics whose differences fall below those thresholds or match the capped precision rule are not published as rows.

Ledger table figure

INDV as-reported XBRL value updates. Compact figure; full filing links are in the page table.INDV as-reported XBRL value updates. Compact figure; full filing links are in the page table.MetricFYThenNowDeltaDelta %Net income2024$2.0M$7.0M$5.0M+71.43%Stockholders' equity2022-$20.0M-$15.0M$5.0M+25.00%Operating income2024$32.0M$38.0M$6.0M+15.79%Stockholders' equity2023-$191.0M-$184.0M$7.0M+3.66%Stockholders' equity2024-$348.0M-$337.0M$11.0M+3.16%Operating income2023-$156.0M-$152.0M$4.0M+2.56%Net income2023-$129.0M-$126.0M$3.0M+2.33%
MetricFYEarliest XBRL-filed valueCurrently on fileDifferenceDifference %LabelFiling linksNotes
Net income
NetIncomeLoss		20242,000,000
filed 2025-03-03 · 10-K		7,000,000
filed 2026-02-26 · 10-K		5,000,000+71.43%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period.
Stockholders' equity
StockholdersEquity		2022-20,000,000
filed 2025-03-03 · 10-K		-15,000,000
filed 2026-02-26 · 10-K		5,000,000+25.00%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period. Earliest observation is a comparative value in a later annual filing.
Operating income
OperatingIncomeLoss		202432,000,000
filed 2025-03-03 · 10-K		38,000,000
filed 2026-02-26 · 10-K		6,000,000+15.79%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period.
Stockholders' equity
StockholdersEquity		2023-191,000,000
filed 2025-03-03 · 10-K		-184,000,000
filed 2026-02-26 · 10-K		7,000,000+3.66%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period. Earliest observation is a comparative value in a later annual filing.
Stockholders' equity
StockholdersEquity		2024-348,000,000
filed 2025-03-03 · 10-K		-337,000,000
filed 2026-02-26 · 10-K		11,000,000+3.16%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period.
Operating income
OperatingIncomeLoss		2023-156,000,000
filed 2025-03-03 · 10-K		-152,000,000
filed 2026-02-26 · 10-K		4,000,000+2.56%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period. Earliest observation is a comparative value in a later annual filing.
Net income
NetIncomeLoss		2023-129,000,000
filed 2025-03-03 · 10-K		-126,000,000
filed 2026-02-26 · 10-K		3,000,000+2.33%revised comparative figure0001625297-25-000016
0001628280-26-012237		2 filed observations examined for this concept and period. Earliest observation is a comparative value in a later annual filing.